{"id":28390,"date":"2024-06-19T18:04:16","date_gmt":"2024-06-19T12:34:16","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=28390"},"modified":"2024-06-21T15:14:45","modified_gmt":"2024-06-21T09:44:45","slug":"pfizers-dmd-gene-therapy","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pfizers-dmd-gene-therapy","title":{"rendered":"Gene therapy: Following Pfizer’s Unexpected Failure, Sarepta is celebrating its much-awaited full approval! Sarepta\u2019s stock price has shot up over 32%"},"content":{"rendered":"\n

Duchenne muscular dystrophy (DMD) is a severe genetic disorder primarily affecting young boys<\/strong> between the ages of two and three. As per Delveinsight\u2019s estimates, there were approximately 16K <\/strong>DMD patients<\/a> in 2023 in the United States, with \u02dc75% of the patients below the age of 15. This condition leads to progressive muscle degeneration, initially presenting as muscle weakness and difficulties with movement. DMD is caused by mutations in the gene responsible for producing dystrophin, a crucial protein for muscle stability and function. <\/p>\n\n\n\n

<\/span><\/p>\n

\n<\/colgroup>\n\n\n\n\n\n\n
\n

Estimated Patient Burden of DMD (2023)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

USA<\/span><\/p>\n<\/td>\n

\n

˜16,000<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

EU4+UK<\/span><\/p>\n<\/td>\n

\n

˜12,000 <\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Japan<\/span><\/p>\n<\/td>\n

\n

˜3,500<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Source: Delveinsight estimates<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n

Market entrants before approval of first DMD gene therapy<\/strong><\/h2>\n\n\n\n

The treatment landscape of DMD<\/a> has majorly centered around managing symptoms and slowing the progression of the disease. Corticosteroids have been the cornerstone of DMD management with more than 70% of the patients on steroids. Beyond steroids, other treatments have focused on supportive care measures. <\/p>\n\n\n\n

\n

\u201cThey\u2019re all these sophisticated modalities with exon skippers or gene therapies coming in. They always come in addition to steroids, so they\u2019re not replacing steroids.\u201d <\/em><\/p>\nIndustry Experts<\/em><\/strong><\/cite><\/blockquote>\n\n\n\n

\"Duchenne<\/figure>\n\n\n\n

In 2016, <\/strong>the barren DMD treatment landscape<\/a> witnessed the approval of its first <\/strong>exon-skipping therapy, Sarepta\u2019s EXONDYS 51<\/strong> for a subset of DMD patients (gene deletions amenable to exon 51 skipping) comprising \u02dc14% of the total DMD patient pool, followed by the approval of VYONDY S53, VILTEPSO, and AMONDYS 45 each targeting \u02dc8% of DMD patients. Except for VILTEPSO, all the other Exon skipping therapies are Sarepta\u2019s, <\/strong>making it the leading player for this hard-to-treat muscular dystrophy in children.\u00a0 Considering weight-based pricing (avg. wt. of 30kg), these Exon skipping therapies were launched at an annual cost of \u02dcUSD 700,000<\/strong> in the United States. After making a strong position in the DMD space, in June 2023 last year, Sarepta\u2019s first one-time gene therapy, ELEVIDYS<\/strong> received approval at a whooping time cost of USD 3.2 million, <\/strong>falling next to Hemgenix\u2019s (approved for Hemophilia B) USD 3.5 million<\/strong> onetime cost, making it the second most expensive gene therapy.<\/p>\n\n\n\n

Sarepta\u2019s wins full approval for ELEVIDYS, and Pfizer\u2019s unfortunate failure<\/strong><\/h2>\n\n\n\n

Last year in June 2023, Sarepta received accelerated approval of ELEVIDYS (delandistrogene moxeparvovec-rokl)<\/strong>, a pioneering gene therapy that delivers a truncated version of the dystrophin gene. Yesterday, the company received full approval based on which the therapy will be available to patients who are at least 4 years old, regardless of whether they can walk. This expands the previous accelerated approval in 4-5-year-old ambulatory patients only.<\/p>\n\n\n\n

In an unfortunate event, Pfizer\u2019s much-awaited DMD gene therapy, fordadistrogene movaparvovec<\/strong>, failed in a Phase III (CIFFREO) trial<\/strong>, expected to address the underlying cause of DMD by delivering a shortened but functional copy of the dystrophin gene, which supposedly was expected to give a tough fight to Sarepta\u2019s ELEVIDYS. The candidate used an AAV9 capsid delivery mechanism to specifically target muscle tissue. However, post fatality issues in a related study, Pfizer\u2019s gene therapy did not cause any improvement in motor function in patients aged 4 to 7 years, thereby providing ELEVIDYS with full opportunity to target patients who are at least 4 year old irrespective of their ambulatory status.<\/p>\n\n\n\n

\"ELEVIDYS<\/figure>\n\n\n\n

What went wrong with Pfizer\u2019s DMD gene therapy?<\/strong><\/h2>\n\n\n\n

Pfizer revealed that Phase III CIFFREO failed to hit its primary goal of improving motor function when compared to placebo at one year of treatment. Key secondary endpoints, such as 10-meter run\/walk velocity and time to rise, also failed to demonstrate a significant difference between fordadistrogene movaparvovec and placebo. Thus, revealing that the treatment failed to meet the main and secondary goals of the study. Before this trial failure, the company reported the death of a young boy participating in the Phase II (DAYLIGHT) trial. The series of failures is a setback for Pfizer as it has added uncertainty around the effectiveness of the therapy. The company will present data from its failed study at a medical meeting later. Additionally, this caused the stocks of Sarepta Therapeutics to go up.<\/p>\n\n\n\n

\n

\u201cWe are extremely disappointed that these results did not demonstrate the relative improvement in motor function that we had hoped. We plan to share more detailed results from the study at upcoming medical and patient advocacy meetings, with the goal of ensuring that learnings from this trial can help improve future clinical research and development of treatment options that can improve care for boys living with Duchenne muscular dystrophy.\u201d<\/em><\/p>\n– Development Head for DMD at Pfizer<\/em><\/cite><\/blockquote>\n\n\n\n

<\/span><\/p>\n

\n
\n<\/colgroup>\n\n\n\n\n\n\n\n
\n

List of other players actively developing Gene therapies for DMD patients<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Drug Name<\/span><\/p>\n<\/td>\n

\n

Company Name<\/span><\/p>\n<\/td>\n

\n

Phase (Trial Identifier)<\/span><\/p>\n<\/td>\n

\n

Patient Segment<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

GNT0004<\/span><\/p>\n<\/td>\n

\n

Genethon<\/span><\/p>\n<\/td>\n

\n

I\/II\/III (<\/span>2020-002093-27)<\/span><\/p>\n<\/td>\n

\n

Age: 6-10 years (ambulatory)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

RGX-202<\/span><\/p>\n<\/td>\n

\n

REGENXBIO<\/span><\/p>\n<\/td>\n

\n

I\/II (NCT05693142)<\/span><\/p>\n<\/td>\n

\n

Age: 4-11 years<\/span>
<\/span>(ambulatory)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

SGT-003<\/span><\/p>\n<\/td>\n

\n

Solid Biosciences<\/span><\/p>\n<\/td>\n

\n

I\/II (NCT06138639)<\/span><\/p>\n<\/td>\n

\n

Age: 4-7 years<\/span><\/p>\n

(ambulatory)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

SERCA2a<\/span><\/p>\n<\/td>\n

\n

Sardocor<\/span><\/p>\n<\/td>\n

\n

I (NCT06224660)<\/span><\/p>\n<\/td>\n

\n

Age: 18 years and older<\/span><\/p>\n

(DMD associated with cardiomyopathy)<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/span><\/div>\n\n\n\n

<\/div>\n\n\n\n

It looks like an unfortunate scenario for Pfizer, considering the strong unmet need in this DMD treatment space<\/a>. However, this is not the first time that any therapy has lacked strong evidence. It was not an easy road for ELEVIDYS as well, over its six-year development period, it was put on two clinical holds, one in 2018 and another in 2021, both as a result of safety concerns as it had also suffered a primary endpoint miss in one of its Phase III studies, however, it\u2019s a win for the company after receiving full approval. Previously, approval of VYONDYS53 and sister medicine EXONDYS51 also fueled concerns for some pharma watchers as they lacked the evidence to show that the drugs could actually improve symptoms or delay disease progression. When there was a data drop during the confirmatory trial of ELEVIDYS, Pfizer got excited and anticipated fordadistrogene movaparvovec to be the main game in the competitive landscape. However, fate had something else planned for this therapy.<\/p>\n\n\n\n

\"Duchenne<\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"

Duchenne muscular dystrophy (DMD) is a severe genetic disorder primarily affecting young boys between the ages of two and three. As per Delveinsight\u2019s estimates, there were approximately 16K DMD patients in 2023 in the United States, with \u02dc75% of the patients below the age of 15. This condition leads to progressive muscle degeneration, initially presenting […]<\/p>\n","protected":false},"author":14,"featured_media":28392,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[1796,218,19107,22155,12860,12861,12862,19884,17916,12863,20821],"industry":[17225],"therapeutic_areas":[17238],"class_list":["post-28390","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-duchenne-muscular-dystrophy","tag-duchenne-muscular-dystrophy-dmd","tag-duchenne-muscular-dystrophy-epidemiology","tag-duchenne-muscular-dystrophy-gene-therapy","tag-duchenne-muscular-dystrophy-market","tag-duchenne-muscular-dystrophy-market-size","tag-duchenne-muscular-dystrophy-pipeline","tag-duchenne-muscular-dystrophy-therapy","tag-duchenne-muscular-dystrophy-treatment","tag-duchenne-muscular-dystrophy-treatment-market","tag-elevidys","industry-pharmaceutical","therapeutic_areas-genetic-disorders"],"acf":[],"yoast_head":"\nPfizer's DMD Gene Therapy Stumbles: A Boost for Sarepta?<\/title>\n<meta name=\"description\" content=\"It looks like an unfortunate scenario for Pfizer, considering the strong unmet need in this DMD treatment space.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pfizers-dmd-gene-therapy\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer's DMD Gene Therapy Stumbles: A Boost for Sarepta?\" \/>\n<meta property=\"og:description\" content=\"It looks like an unfortunate scenario for Pfizer, considering the strong unmet need in this DMD treatment space.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pfizers-dmd-gene-therapy\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-19T12:34:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-21T09:44:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/19155544\/pfizers-dmd-gene-therapy.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer's DMD Gene Therapy Stumbles: A Boost for Sarepta?","description":"It looks like an unfortunate scenario for Pfizer, considering the strong unmet need in this DMD treatment space.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pfizers-dmd-gene-therapy","og_locale":"en_US","og_type":"article","og_title":"Pfizer's DMD Gene Therapy Stumbles: A Boost for Sarepta?","og_description":"It looks like an unfortunate scenario for Pfizer, considering the strong unmet need in this DMD treatment space.","og_url":"https:\/\/www.delveinsight.com\/blog\/pfizers-dmd-gene-therapy","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-06-19T12:34:16+00:00","article_modified_time":"2024-06-21T09:44:45+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/19155544\/pfizers-dmd-gene-therapy.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pfizers-dmd-gene-therapy","url":"https:\/\/www.delveinsight.com\/blog\/pfizers-dmd-gene-therapy","name":"Pfizer's DMD Gene Therapy Stumbles: A Boost for Sarepta?","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pfizers-dmd-gene-therapy#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pfizers-dmd-gene-therapy#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/19155544\/pfizers-dmd-gene-therapy.png","datePublished":"2024-06-19T12:34:16+00:00","dateModified":"2024-06-21T09:44:45+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"It looks like an unfortunate scenario for Pfizer, considering the strong unmet need in this DMD treatment space.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pfizers-dmd-gene-therapy"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pfizers-dmd-gene-therapy#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/19155544\/pfizers-dmd-gene-therapy.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/19155544\/pfizers-dmd-gene-therapy.png","width":466,"height":284,"caption":"pfizers-dmd-gene-therapy"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/19155544\/pfizers-dmd-gene-therapy-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Duchenne muscular dystrophy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Duchenne muscular dystrophy (DMD)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Duchenne Muscular Dystrophy Epidemiology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Duchenne muscular dystrophy gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Duchenne Muscular Dystrophy Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Duchenne Muscular Dystrophy Market Size<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Duchenne Muscular Dystrophy Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Duchenne muscular dystrophy therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Duchenne Muscular Dystrophy Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Duchenne Muscular Dystrophy Treatment Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ELEVIDYS<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Duchenne muscular dystrophy<\/span>","<span class=\"advgb-post-tax-term\">Duchenne muscular dystrophy (DMD)<\/span>","<span class=\"advgb-post-tax-term\">Duchenne Muscular Dystrophy Epidemiology<\/span>","<span class=\"advgb-post-tax-term\">Duchenne muscular dystrophy gene therapy<\/span>","<span class=\"advgb-post-tax-term\">Duchenne Muscular Dystrophy Market<\/span>","<span class=\"advgb-post-tax-term\">Duchenne Muscular Dystrophy Market Size<\/span>","<span class=\"advgb-post-tax-term\">Duchenne Muscular Dystrophy Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Duchenne muscular dystrophy therapy<\/span>","<span class=\"advgb-post-tax-term\">Duchenne Muscular Dystrophy Treatment<\/span>","<span class=\"advgb-post-tax-term\">Duchenne Muscular Dystrophy Treatment Market<\/span>","<span class=\"advgb-post-tax-term\">ELEVIDYS<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Jun 19, 2024","modified":"Updated on Jun 21, 2024"},"absolute_dates_time":{"created":"Posted on Jun 19, 2024 6:04 pm","modified":"Updated on Jun 21, 2024 3:14 pm"},"featured_img_caption":"pfizers-dmd-gene-therapy","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28390","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=28390"}],"version-history":[{"count":6,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28390\/revisions"}],"predecessor-version":[{"id":28429,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28390\/revisions\/28429"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/28392"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=28390"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=28390"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=28390"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=28390"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=28390"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}